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Abstract
Treat-to-target (T2T) is an emerging treatment paradigm in axial spondyloarthritis (axSpA), originally based
on evidence from other inflammatory conditions, which aims to direct therapy to a clear target such as
disease remission or low disease activity, with the ultimate goal of maximizing quality of life in affected
individuals. The 2016 update of the Assessment of Spondyloarthritis International Society/EULAR guide-
lines for axSpA have recommended that treatment should be guided according to a predefined target but
controversy remains as to what this target should be. An international task force has recommended
remission or inactive disease as the desired outcome; however, there are many disease outcome meas-
ures developed for use in clinical practice in axSpA and the question remains of which is the most
appropriate to use. Another important consideration when discussing the T2T paradigm is when to inter-
vene. Although evidence is limited in this respect, the available data suggest that therapy should be
commenced at an early stage of the disease, when the process of bone repair expected to occur after
an inflammatory phase has not yet started. It has also been argued that the success of the T2T paradigm
may depend more on the treatment strategy than the individual therapies utilized. This article will explore
the feasibility of using a T2T approach in axSpA clinical practice, the utilization of new composite outcome
measures of disease activity such as the ASDAS, and the validity of different treatment strategies to allow
for a T2T intervention in these patients.
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Rheumatology key messages
. The main treatment goal in axial SpA is the maximization of long-term quality of life.
. Symptom control, preservation of function and social participation are key in axial SpA.
. Treat-to-target in axial SpA may depend on achieving an early state of remission with complete suppression of
disease activity.
Introduction
The treatment of axial spondyloarthritis (axSpA) requires a
combination of pharmacological and non-pharmacological
treatment modalities and has as its main goal the maxi-
mization of long-term health-related quality of life through
control of symptoms and inflammation, prevention of pro-
gressive structural damage, preservation/normalization
of function and social participation [1]. Given the variability
in the predominance of disease manifestations among pa-
tients and the multifactorial nature of the treatment goal,
the measurement of its successful achievement is com-
plex and is currently a matter of research and discussion
among clinicians. In this article, we will discuss the most
recent developments in the treat-to-target (T2T) paradigm
and recommendations for what to target and when to
intervene, as well as considerations of and the latest
data on treatment strategies.
T2T paradigm in axSpA
T2T is emerging as a new paradigm in the treatment of
inflammatory arthritis, and particularly RA. This is based
on evidence from other chronic conditions where it has
been shown to be a pragmatic and cost-effective strat-
egy. For example, the application of a T2T paradigm has
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resulted in the prevention of microvascular complications
such as retinopathy and nephropathy in patients with type 2
diabetes mellitus, and in a significantly reduced risk of
cardiovascular death in patients with hypertension [2, 3].
In chronic inflammatory arthritis, T2T aims to direct ther-
apy to a clear target, such as disease remission or low
disease activity, which should be sustained over time.
This concept involves regular disease activity monitoring
and a clear understanding of flares, and ideally aims at
tight control. Evidence in early RA supports the benefits of
this paradigm in the prevention of damage, maintenance
of physical function and reduction of comorbidity risks [4].
Furthermore, emerging data support the validity of this
approach in established RA, in elderly patients and to im-
prove work capacity [4]. T2T has also been advocated for
PsA, for which a validated definition of minimum disease
activity is already available [5].
The 2016 update of the Assessment of Spondyloarthritis
International Society (ASAS) and the EULAR guidelines
included a new recommendation supporting the T2T para-
digm in axSpA. There are, however, significant challenges
in facilitating its implementation [6]. For example, unlike in
RA, the relationship between uncontrolled inflammation
and joint damage has not been unequivocally shown in
axSpA, which, coupled with the scarcity of data on what
the target should be and when to intervene, illustrates some
of the obstacles faced by clinicians and researchers
involved in the care of these patients.
The recently updated recommendations by an interna-
tional task force on the T2T paradigm highlight remission
or inactive disease of the musculoskeletal and extra-
articular manifestations of axSpA as the desired outcome
[7]. However, there is still debate as to what the ideal
target should be in order to achieve the desired outcome
of disease inactivity or remission.
Relationship between inflammation and joint damage
One of the main outcome measures in axSpA is the loss of
function through bone neo-formation or joint fusion at the
levels of both the SIJ and the spine. This progression ap-
pears to be generally linear over time, with a quarter of
affected individuals progressing rapidly at the beginning
of their disease [8]. A logical group to target would, there-
fore, be those with the more severe disease phenotype,
who are likely to progress faster.
Data from a number of recent studies have indicated
that radiographic progression is higher than average in
people who have a high level of CRP at baseline [9, 10]
and those who have evidence of inflammation, particularly
severe SIJ bone marrow oedema (BMO) [11]. Taken to-
gether, these data indicate that there is a link between
inflammation and new bone formation suggesting that
both high CRP and BMO lesions are suitable targets for
intervention. However, an important consideration re-
mains that these inflammatory biomarkers are not univer-
sal, occurring only in 7080% of patients with axSpA [12].
Further evidence suggests that individuals who have
existing syndesmophytes at baseline (i.e. evidence of es-
tablished bone neo-formation) progress much faster than
those without [13]; this is particularly true for men and
patients who smoke [14, 15]. However, the molecular
basis underpinning this process remains poorly under-
stood and, although a relationship with inflammation has
been shown, there remains uncertainty over when and
how these processes of inflammation and new bone for-
mation are linked. Indeed, prospective studies have
shown progression of spinal syndesmophyte formation
in the absence of MRI inflammation, despite ongoing
TNF inhibitor (TNFi) therapy over 2 years [16, 17].
However, recent, long-term, retrospective analyses have
suggested that long-term TNFi therapy can retard radio-
graphic progression [1820], while a prospective study of
the Swiss Clinical Quality Management cohort of axSpA
patients also demonstrated a reduced risk of radiographic
progression with TNFi use, as assessed by new syndes-
mophyte formation and the modified Stoke Ankylosing
Spondylitis Spinal Score [21].
Outcomes and targets
Despite a growing number of outcome measures de-
veloped for use in clinical practice on subjects with
axSpA, the majority fail to incorporate all aspects of the
disease, such as its impact on quality of life or extra-ar-
ticular manifestations.
The recently developed ASDAS has been shown to
have good discriminatory capacity and sensitivity to
change and incorporates an objective measure of disease
activity such as CRP or ESR [22, 23]. In addition, ASDAS
has well-validated cut-offs: inactive disease (<1.3), mod-
erate (1.32.0), high (2.13.5) and very high disease
activity (>3.5), with evidence suggesting that ASDAS in-
active disease (<1.3) can be considered a possible target
and remission criterion in axSpA [24]. ASDAS has a pos-
sible advantage over the ASAS response criteria because
the latter incorporate a function domain (the BASFI) that
makes them less sensitive to change in advanced dis-
ease, when improvements in physical function are likely
to be limited [25]. Yet, clinical trials show that only a small
proportion of patients achieve ASDAS inactive disease
after treatment with biologics, that is, patients with more
advanced disease [2629].
T2T paradigm in axSpA: when
to intervene
An important consideration when discussing the T2T
paradigm in axSpA is when to intervene. Emerging data
point towards the importance of targeting disease activity,
as this leads to progression with further syndesmophyte
formation [10, 15]. However, this approach may only be
relevant in established AS cases with not only SIJ but also
spinal involvement, as these are the cases for which
new syndesmophyte formation has been proven to be
linked to existing baseline syndesmophytes [30]. These
data cannot yet be extrapolated to earlier disease
stages in axSpA or to those patients who have radio-
graphic sacroiliitis but may never develop spinal
syndesmophytes.
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Studies and analyses have been conducted to deter-
mine the effect of duration and stage of disease on re-
sponse to treatment with TNFis. Among these is a study
by Haibel et al. [31] investigating adalimumab in 46 pa-
tients with active axSpA, which demonstrated that 80%
(12/15 patients) with a disease duration of 43 years at
baseline vs 14.3% (1/7 patients) with a disease duration
of >10 years at baseline achieved a BASDAI 50 response
and 73.3% (11/15 patients) vs 0% of patients, respect-
ively, achieved an ASAS 40 response [31]. A study by
Barkham et al. [32] was the first to demonstrate that inflix-
imab is effective for reducing clinical and imaging evi-
dence of disease activity in a cohort of patients with
very early non-radiographic axial SpA (nr-axSpA) in
whom progression to AS is highly likely. Furthermore,
when results from this study were compared with those
of a study of infliximab in established AS, it was shown
that the proportion of patients reaching the ASAS partial
remission criteria was higher for early axSpA (55.6 vs
22.4%) [32, 33]. Taken together, these data suggest that
the extent of disease and the point of diagnosis are rele-
vant to the success of the treatment.
Further indirect support for earlier intervention comes
from imaging studies exploring the relationship between
oedematous and fatty lesions in the SIJ and spine, which
suggest that fat deposition is a post-inflammatory event
[34]. However, data suggest that resolution of acute in-
flammatory lesions of BMO does not stop radiographic
progression when fat metaplasia deposition occurs after
resolution of inflammation [35]. Indeed new bone forma-
tion appears more likely to occur if there is fat develop-
ment at any point, independent of treatment, rather than in
the presence of BMO lesions that resolve completely [36].
Studies utilizing PETCT have revealed osteoblastic activ-
ity in these fatty lesions [37]. These observations were
confirmed in a recent study that analysed biopsies ob-
tained by spinal surgery: MRI-determined fatty lesions
were indeed shown to correspond to fatty cells in the
bone marrow with the potential to develop osteoblastic
activity [38]. These data would point towards BMO MRI
lesions as a valid target for early intervention, before the
process of fat transformation has started.
Treatment strategies
It has been argued that the T2T paradigm may depend on
the treatment strategy employed more than the individual
therapies, and also on the achievement of an early state of
remission with complete suppression of disease activity.
This is supported by the results of a study, showing that
patients with axSpA including AS with a disease duration
of <2 years who received combination treatment of inflix-
imab and NSAIDs were twice as likely to achieve clinical
remission as patients who received NSAIDs alone [39].
A subsequent study in the same patient population
confirmed that 50% of patients who had achieved partial
remission after 28 weeks of treatment remained in remis-
sion after 6 months regardless of the treatment strategy
used [40]. A further study suggested that the combination
of a TNFi and high-dose NSAIDs led to better outcomes
and less progression over time compared with single ther-
apy, whether that is a TNFi or NSAID [41].
To confirm these findings, validated definitions of remis-
sion and flare are needed. In addition, a greater under-
standing of whether remission of clinical symptoms and
signs correlates with complete arrest of disease progres-
sion is required. For example, recent studies have shown
conflicting data on the ability of NSAIDs to slow radio-
graphic progression in AS despite a good clinical re-
sponse [42]. Imaging studies have shown the efficacy of
TNFis in reducing inflammation, correlating with significant
improvements in subjective and objective measures of
disease activity [43], while a growing body of evidence
suggests that they also effectively inhibit radiographic
progression [21, 44, 45]. Similar results have been
shown with other biologic agents such as the IL-17A in-
hibitor secukinumab, although importantly the MEASURE
studies lacked either a long-term placebo or standard-of-
care control [4648].
Nevertheless, it is noteworthy that radiographic pro-
gression occurs slowly and may only be relevant in a
subset of patients with so-called poor prognostic factors,
meaning it may not be a useful universal outcome
measure in AS.
Conclusions
The treatment armamentarium for AS continues to
expand. Although clinical guidelines recommend the ap-
plication of a T2T paradigm for the treatment of axSpA,
much debate and uncertainty remain on what an ad-
equate target should be, when intervention should occur
and what role treatment strategy will play. Further re-
search is needed to clarify these points and validated def-
initions of remission and flare are needed; however, the
current evidence suggests that therapy should be aimed
at an early stage of disease before the processes of fat
transformation and new bone formation have started. It is
important that the assessments used to monitor long-term
response in routine clinical practice reflect the overarching
goals of treatment.
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